Martinsried, Germany, October 21, 2009 / b3c newswire / - KINAXO Biotechnologies GmbH announced today that it has entered into a collaboration with Roche Diagnostics GmbH in Penzberg, Germany. Under the agreement KINAXO's phosphoproteomics technology PhosphoScout® will be applied to support the identification of biomarkers related to new treatment approaches based on therapeutic antibodies currently under development at Roche. Financial details of the agreement were not disclosed.
PhosphoScout® is a global, quantitative phosphoproteomics service tailored to dissect cellular signal transduction pathways and their response to drug treatment. The technology is based on proprietary mass spectrometry methods, which enable the unbiased analysis of 15,000 phosphorylation sites in a single experiment.
Dr. Klaus Godl, KINAXO’s CSO commented: “We are very pleased to partner with Roche, a world leading healthcare company. Cellular signal transmission in eukaryotic cells is mainly regulated by the reversible phosphorylation of proteins. Therefore, differential analysis of the complete cellular phosphoproteome upon drug treatment provides highly informative insights into the modes of action of targeted cancer drugs.”
About KINAXO - www.kinaxo.com
KINAXO Biotechnologies is a privately-held biotechnology company based in Munich/Martinsried, Germany. KINAXO offers extensive experience in chemical proteomics technologies for drug mode-of-action analysis, cellular target profiling, target deconvolution, and drug repositioning. KINAXO maintains several collaborations with global pharmaceutical companies, such as Johnson & Johnson, Bayer and Boehringer Ingelheim.
Dr. Jutta Fritz, MBA, Head of Technology and Business Development
KINAXO Biotechnologies GmbH
Am Klopferspitz 19a
Phone +49 89 4613363-22